10-Q: Catheter Precision Reports Q2 2024 Results, Cites Ongoing Losses and Going Concern Uncertainty

Catheter Precision's Q2 2024 results reveal continued operating losses and a substantial doubt about the company's ability to continue as a going concern.

Summary

• Catheter Precision reported a net loss of $6.9 million for the six months ended June 30, 2024, compared to a net loss of $68 million for the same period in 2023.
• The company's cash and cash equivalents stood at $16 thousand as of June 30, 2024, and it used $3.6 million in cash for operating activities during the first six months of 2024.
• Revenues for the first six months of 2024 were $175 thousand, a slight decrease from $181 thousand in the same period of 2023.
• The company has an accumulated deficit of $282.6 million as of June 30, 2024.
• Management has expressed substantial doubt about the company's ability to continue as a going concern for a period of one year after the date the unaudited condensed consolidated financial statements are issued.
• The company is evaluating potential means of raising cash through future capital transactions and additional bridge loans.

Sentiment

Score: 2

Explanation: The document indicates a very negative sentiment due to the company's significant losses, low cash reserves, and going concern uncertainty. While there are some positive developments, such as the launch of LockeT and sales force expansion, the overall financial situation is dire.

Positives

• The company began sales of its new LockeT product in Q2 2024.
• The company has expanded its sales force and hired a new Chief Commercial Officer.
• The company has made changes to the manufacturing process of VIVO Positioning Patches, reducing costs by approximately 40%.

Negatives

• The company's cash position is critically low, with only $16 thousand in cash and cash equivalents as of June 30, 2024.
• The company has incurred significant net losses and negative cash flows from operations.
• Management has expressed substantial doubt about the company's ability to continue as a going concern.
• The company has identified material weaknesses in its internal control over financial reporting.
• The company has a total of $1.5 million of short-term loans that will become due and payable on August 30, 2024.

Risks

• The company may not be able to secure additional financing in a timely manner or on favorable terms.
• The company may be required to reduce its spending rate to align with expected revenue levels and cash reserves.
• The company's ability to continue as a going concern is uncertain.
• The company has identified material weaknesses in its internal control over financial reporting.
• The company faces product liability risks related to its VIVO and LockeT products.
• The company's business relationship with distributors and/or persons in Qatar and elsewhere in the Middle East could be disrupted by the armed conflict in Israel and the Gaza strip and/or changes in U.S. international relations and/or related geopolitical changes.

Future Outlook

The company expects operating losses and negative cash flows to continue for the foreseeable future as it invests in its commercial capabilities. The company is evaluating potential means of raising cash through future capital transactions and additional bridge loans. The company anticipates CE Mark approval for LockeT in the second half of 2024.

Management Comments

• Management expects operating losses and negative cash flows to continue for the foreseeable future as the Company invests in its commercial capabilities.
• Management will continue to monitor its operating costs and seek to reduce its current liabilities.
• Management has concluded that there is substantial doubt about the Company's ability to continue as a going concern for a period of one year after the date the unaudited condensed consolidated financial statements are issued.

Industry Context

The company operates in the competitive medical device industry, specifically in the field of cardiac electrophysiology. The company's focus on innovative technologies like the VIVO System and LockeT positions it to address unmet needs in this market. However, the company faces challenges in achieving profitability and securing sufficient funding to support its operations.

Comparison to Industry Standards

• The company's financial performance is significantly below industry standards for medical device companies, particularly in terms of profitability and cash flow.
• Many comparable medical device companies have established revenue streams and positive cash flow, while Catheter Precision is still in the early stages of commercialization and is facing significant financial challenges.
• Companies like Biosense Webster (a subsidiary of Johnson & Johnson) and Abbott are major players in the cardiac electrophysiology market with significantly greater resources and established market presence.
• The company's reliance on external funding and its going concern uncertainty are not typical for established medical device companies.

Management Changes

Related Party Transactions

• David A. Jenkins, Executive Chair and Chief Executive Officer, and his affiliates hold a significant amount of the company's Series X Convertible Preferred Stock.
• Mr. Jenkins and his affiliates received royalty rights equal to approximately 12% of the net sales of LockeT.
• Mr. Jenkins loaned $500,000 to the company in exchange for a short term promissory note.
• An entity controlled by Mr. Jenkins loaned $150,000 to the company in exchange for a short term promissory note.
• A Trust, of which Mr. Jenkins adult daughter is the trustee, loaned $500,000 to the company in exchange for a short term promissory note.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and going concern uncertainty.
• Employees may be affected by potential cost-cutting measures or operational changes.
• Customers may be concerned about the company's ability to continue providing products and services.
• Suppliers and creditors face increased risk of non-payment due to the company's financial difficulties.

Next Steps

• The company will continue to monitor its operating costs and seek to reduce its current liabilities.
• The company will evaluate potential means of raising cash through future capital transactions and additional bridge loans.
• The company will continue to develop and commercialize its novel electrophysiology technologies and solutions.
• The company expects CE Mark approval for LockeT in the second half of 2024.

Key Dates

Keywords

Catheter Precision, VIVO System, LockeT, cardiac electrophysiology, medical devices, financial results, going concern, operating losses, cash flow, capital raise, internal control, product sales, revenue, net loss, warrants, preferred stock, reverse stock split